NASDAQ:DOMH Dominari 5/9/2024 Earnings Report $4.41 -0.44 (-9.07%) As of 07/30/2025 04:00 PM Eastern ProfileEarnings History Dominari EPS ResultsActual EPS-$0.35Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADominari Revenue ResultsActual Revenue$1.37 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADominari Announcement DetailsQuarterDate5/9/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsDominari's next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Dominari Earnings HeadlinesDominari Securities Serves as Exclusive Placement Agent to SRM Entertainment on a $100 Million Equity InvestmentJune 17, 2025 | prnewswire.comDominari Holdings Set to Join Russell Microcap® IndexMay 28, 2025 | prnewswire.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains. | Weiss Ratings (Ad)Boutique Trump Tower Bank Is Quietly Stockpiling Bitcoin: BloombergMay 19, 2025 | news.bitcoin.comDominari Holding's Strategic Interest in Bitcoin Mining Set to Go PublicMay 13, 2025 | prnewswire.comDominari Holdings files to sell 13.94M shares of common stock for holdersApril 21, 2025 | markets.businessinsider.comSee More Dominari Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dominari? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dominari and other key companies, straight to your email. Email Address About DominariDominari (NASDAQ:DOMH), a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.View Dominari ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Deckers Stock Recovers on Strong Earnings—More Upside Ahead?3 Reasons Tesla's Post-Earnings Hangover Looks Like a BuyCan Qualcomm Shock Wall Street With Its Q3 Earnings?T-Mobile Earnings Show You Why This Is a Stock to Hold Upcoming Earnings Linde (8/1/2025)Regeneron Pharmaceuticals (8/1/2025)Enbridge (8/1/2025)Dominion Energy (8/1/2025)Colgate-Palmolive (8/1/2025)Southern Copper (8/1/2025)Exxon Mobil (8/1/2025)Chevron (8/1/2025)Ares Management (8/1/2025)W.W. Grainger (8/1/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
